Reference is made to the successfully contemplated rights issue in Softox
Solutions AS (the "Company"). As earlier announced, the underwriters of the
rights issue will receive a guarantee commission of 10 % on the secured sum of
NOK 22 500 000, allocated proportionally based on each underwriter's guaranteed
amount.

The Company also has outstanding amounts to two former employees, Geir Almås and
Christian Harstad, following settlements regarding the termination of their
contractual relationship with the Company. Both Almås and Harstad have consented
to receive part of their owed remuneration in the form of new shares in the
Company. 

For more information, please see the stock exchange announcements published by
Company on August 12, 2024.

Additionally, the Company has resolved a dispute amicably with a former
consultant concerning patent application disagreements. As per the settlement,
the consultant is to be compensated with new shares in the Company at their
nominal value.

The Company, along with the aforementioned claimants, has agreed to settle these
obligations by converting the outstanding amounts into new shares in the
Company.

Consequently, the Board of Directors, pursuant to authorization granted at the
Company's Extraordinary General Meeting on 31st of August 2024, has decided to
issue 196 976 042 new shares in favor of the aforesaid persons. 

The subscription prices for the new shares, as determined by individual
agreements with the aforementioned claimants, are as follows:
o112 500 000 shares at NOK 0,02 per share
o58 326 042 shares at NOK 0,0234 per share
o9 900 000 shares at NOK 0,0234 per share
o16 250 000 shares at NOK 0,04 per share

The total subscription amount in the capital increase is NOK 4,496,489.39.

Following registration of the share capital increases pertaining to the
issuances of new shares, the share capital will be NOK 39 025 078,84 divided
into 1 951 253 942 shares, each with a nominal value of NOK 0.02.
  
About SoftOx Solutions AS  
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes the holding
company SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB (WIAB),
and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx
is developing a highly effective antimicrobial solution for use in biofilm,
viral, and antimicrobial-resistant infections. The patent-protected technology
is based on extensive research and development in partnership with leading
Nordic research institutes. 

For more information on SoftOx, visit www.soft-ox.com